Drug maker Lupin today said it has received approval from the US health regulator to market anti-inflammatory Clobetasol Propionate lotion in the American market.
The Mumbai-based firm said in a statement that it has received final approval for its product from the US Food and Drug Administration (USFDA).
The company's product is a generic version of Galderma Laboratories' Clobex Lotion, which is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
As per IMS MAT June data, Clobex had sales of USD 14.3 million in the US market.
Lupin shares were trading 1.6 per cent down at Rs 997.3 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
